Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. The company was founded in 1996 and is headquartered in Canada. Xenon is advancing an exciting product pipeline to address indications with high unmet medical needs, including epilepsy and depression. The flagship XEN1101 program represents the most advanced potassium channel modulator in clinical development for multiple indications. Following positive results from the XEN1101 Phase 2b “X-TOLE” study in adult patients with focal epilepsy, Xenon has multiple Phase 3 clinical trials in the pipeline. In addition, the company plans to initiate a Phase 3 XEN1101 program in major depressive disorder in 2024, based on topline data from the XEN1101 Phase 2 “X-NOVA” clinical trial. Xenon also focuses on leading-edge science from its discovery labs, with early-stage research programs leveraging extensive ion channel expertise and drug discovery capabilities. The company received a significant $300.00M Post-IPO Equity investment on 29 November 2023.
Xenon Pharmaceuticals Inc.
A neuroscience-focused biopharmaceutical company
Canada
333 employees
Post Ipo Equity
Total: $1.29B
Biopharma, Biotechnology +2
General Information
Get notified when Xenon Pharmaceuticals Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Xenon Pharmaceuticals Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Canada Market
Biopharma
About Xenon Pharmaceuticals Inc.
Taxonomy: biopharmaceuticals, neuroscience, drug development, ion channels, neurology, epilepsy, depression, psychiatry, seizures, potassium channels, sodium channels, clinical trials, genetic insights, rare genetic disorders, proprietary discovery platform
Funding Rounds & Investors (13)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | - | 29 Nov 2023 | |
| Post-IPO Equity | •••••• | - | 22 Jun 2022 | |
| Post-IPO Equity | •••••• | - | 05 Oct 2021 | |
| Post-IPO Equity | •••••• | - | 10 Mar 2021 | |
| Post-IPO Equity | •••••• | - | 22 Jan 2020 |
Xenon Pharmaceuticals Inc. Alternatives & Competitors
At Phanes, we bring innovation that illuminates the path to cure.
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VD...
Pioneering next-gen therapeutics to harness C1q's central role in neuroinflammatory diseases.
FAQ About Xenon Pharmaceuticals Inc.
Don't just browse. Track.
Signal Tracker monitors Xenon Pharmaceuticals Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
